Condition: Colorectal Cancer · Liver Metastasis · LDRT · Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.
This description comes directly from the study's public registry record.
Chuan Chen, MD PhD · 13883089634 · sinkriver@126.com
Always discuss trial participation with your own doctor first.
| Army Medical Center | Chongqing, Chongqing Municipality, China | Recruiting |
| Daping Hospital, Army Medical University | Chongqing, Chongqing Municipality, China | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06848465